<DOC>
	<DOCNO>NCT02623933</DOCNO>
	<brief_summary>Radiation therapy play important role management prostate cancer . In recent year become evident high dos radiation require optimize disease control . The limiting factor escalate dose prostate surround normal tissue . Despite advance escalate radiation therapy , failure still occur 20-30 % patient often site original primary disease . As grow interest dose escalate area primary disease burden.The aim work look feasibility toxicity integrate focal boost whole gland prostate treatment use high dose rate brachytherapy .</brief_summary>
	<brief_title>MRI Assisted Focal Boost With HDR Monotherapy Prostate Cancer Patients</brief_title>
	<detailed_description>This study pilot study 60 patient look toxicity , biochemical patient report quality life outcomes MR-integrated focal boost use HDR prostate brachytherapy . Eligible patient study determine pre-brachytherapy MRI ( DCE , T2 weight diffusion weight ) imaging , identify dominant intraprostatic lesion . The HDR dose prescription 19 Gy whole gland ad 22.5 Gy MRI visible lesion deliver one fraction , assume dose constraint critical organ meet .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm diagnosis adenocarcinoma prostate 2 . Low Intermediate risk disease define T1T2c , Gleason &lt; 7 PSA &lt; 20 ng/ml . 3 . Prostate volume &lt; 60 cc determine US , CT MRI 4 . Ability undergo MR image 5 . Provide write informed consent 6 . Identified MR nodule ( PIRADs 4/5 ) 1 . Ineligible MR imaging due contraindication 2 . Documented nodal distant metastasis 3 . Previous pelvic radiotherapy 4 . Previous transurethral resection prostate , previous prostatectomy HIFU 5 . Use androgen deprivation therapy . Use 5alphareductase inhibitor permit 6 . Poor baseline urinary function define International Prostate Symptom Score ( IPSS ) &gt; 15 7 . Contraindication radical prostate radiotherapy e.g . connective tissue disease inflammatory bowel disease 8 . Significant medical comorbidity render patient unsuitable general anaesthetic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HDR monotherapy</keyword>
	<keyword>MRI guidance</keyword>
	<keyword>Intraprostatic lesion</keyword>
	<keyword>dose pain</keyword>
</DOC>